Want to see XWEL full AI Analyst Report?
XWEL Stock Chart & Stats
$0.50
-$0.02(-1.34%)
At close: 4:00 PM EST
$0.50
-$0.02(-1.34%)
Day’s Range― - ―
52-Week Range$0.26 - $2.20
Previous CloseN/A
Volume7.98K
Average Volume (3M)79.79K
Market Cap
$9.04M
Enterprise Value$9.70
Total Cash (Recent Filing)$16.81M
Total Debt (Recent Filing)$8.31M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.59
Shares Outstanding8,444,266
10 Day Avg. Volume196,854
30 Day Avg. Volume79,787
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.12
Price to Sales (P/S)0.09
P/FCF Ratio-0.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic DivestitureThe announced sale of XpresSpa/XpresTest for a $13M base aims to simplify the portfolio and provide material proceeds to shore up liquidity and reduce operating complexity. As a structural move, it can materially improve capital allocation and balance-sheet flexibility over the medium term if completed.
Improved Gross MarginGross margins stabilizing in the mid-20% range versus prior troughs indicates the business can generate healthier unit economics. Sustained mid-20% gross margin gives management room to address fixed operating cost base and creates a clearer path to narrowing operating losses if revenue stabilizes or fixed costs are reduced.
Board & Investor SupportFormal vote commitments from the board and key investors reduce execution risk for the divestiture and strategic pivot. Strong internal alignment makes approvals and potential follow-on financing or restructurings more likely to succeed, improving prospects for orderly balance-sheet repair.
Bears Say
Very Thin Equity And High LeverageExtremely low equity relative to debt leaves a minimal capital cushion against continued losses. High leverage constrains strategic options, elevates insolvency risk if cash flows worsen, and increases the probability of dilutive or distressed financing being required to sustain operations over the coming months.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow signal the company consumes significant cash to run existing operations. Without reliable external financing or material cost reductions, ongoing cash burn threatens continuity, limits reinvestment, and pressures near-term liquidity independent of strategic asset sales.
Shrinking Revenue And Deep Net LossesMaterial revenue decline combined with very large negative net margins indicates core demand or footprint issues and that current cost structure is misaligned with scale. Structural revenue weakness makes profitable recovery harder and increases reliance on non-operating remedies like asset sales or restructuring.
XWELL News
XWEL FAQ
What was XWELL’s price range in the past 12 months?
XWELL lowest stock price was $0.26 and its highest was $2.20 in the past 12 months.
What is XWELL’s market cap?
XWELL’s market cap is $9.04M.
When is XWELL’s upcoming earnings report date?
XWELL’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were XWELL’s earnings last quarter?
Currently, no data Available
Is XWELL overvalued?
According to Wall Street analysts XWELL’s price is currently Overvalued.
Does XWELL pay dividends?
XWELL does not currently pay dividends.
What is XWELL’s EPS estimate?
XWELL’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XWELL have?
XWELL has 8,444,266 shares outstanding.
What happened to XWELL’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of XWELL?
Currently, no hedge funds are holding shares in XWEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XWELL
XWELL Inc. functions as a health and wellness services provider, primarily operating within airports. The company delivers its diverse offerings through various brands, including XpresSpa, XpresTest, Treat, and HyperPointe. Its core services feature a range of spa treatments such as massages, nail care, and skincare, further complemented by the sale of spa, travel, and general retail merchandise. Beyond relaxation services, XWELL also manages dedicated wellness centers. These facilities provide crucial health diagnostic services, encompassing COVID-19 screening and testing, rapid tests for various communicable diseases like influenza, RSV, and different flu strains (A&B), alongside seasonal flu vaccinations and other medical diagnostic procedures. To enhance accessibility for the traveling public, the company utilizes an integrated digital platform and a tailored retail selection. As of December 31, 2021, XWELL maintained a significant global presence, with 52 spa and clinic locations spanning 24 airports across the United States, the Netherlands, and the United Arab Emirates. The organization, headquartered in New York, New York, underwent a name change in October 2022, transitioning from its former identity as XpresSpa Group, Inc. to its current designation, XWELL Inc.
Technical Analysis
Medifast
―
Regis
―
MEDIROM Healthcare Technologies
―
E-Home Household Service Holdings
―
Interactive Strength Inc
―
Ownership Overview
13.71% Insiders
1.23% Mutual Funds
<0.01% Other Institutional Investors
84.45% Public Companies and
Individual Investors